Esperion Therapeutis.Inc. buy OrderProvision70
Start price
18.04.25
/
50%
€0.79
Target price
18.05.25
-
Performance (%)
-8.23%
End price
19.05.25
€0.72
Summary
This prediction ended on 19.05.25 with a price of €0.72. With a performance of -8.23%, the BUY prediction by OrderProvision70 finished with a loss. OrderProvision70 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | - | - | - |
| iShares Core DAX® | 2,59 % | 2,69 % | 6,41 % |
| iShares Nasdaq 100 | -0,91 % | -7,37 % | 20,65 % |
| iShares Nikkei 225® | 0,15 % | -10,20 % | 46,17 % |
| iShares S&P 500 | -0,37 % | -0,83 % | 18,02 % |
Comments by OrderProvision70 for this prediction
In the thread Trading Esperion Therapeutis.Inc.
Die von OrderProvision70 gewählte maximale Laufzeit wurde überschritten